TELA Bio (TELA) Q4 & FY 2025 Earnings Transcript

Call ParticipantsThe key participants in this earnings discussion included Antony Koblish, the Chief Executive Officer; Jeffrey Blizard, the President; Roberto E. Cuca, the Chief Financial Officer; and Jim Hagen, the Chief Commercial Officer. Their insights provided a comprehensive overview of the c

Call Participants

The key participants in this earnings discussion included Antony Koblish, the Chief Executive Officer; Jeffrey Blizard, the President; Roberto E. Cuca, the Chief Financial Officer; and Jim Hagen, the Chief Commercial Officer. Their insights provided a comprehensive overview of the company’s performance and strategic direction during the period.

Key Financial Highlights

During the fourth quarter, the company reported revenue of $20.9 million, marking an impressive 18% increase compared to the same quarter in the previous year. For the full year, revenue reached $80.3 million, reflecting a solid 16% growth year over year. These figures underscore the company’s ability to drive consistent expansion despite ongoing organizational transitions.

OviTex revenue demonstrated steady growth, rising 12% over the full year, while OviTex PRS revenue saw even stronger momentum with a 20% increase in the same timeframe. This performance highlights the broadening appeal of the product portfolio across different surgical applications.

In terms of unit sales, OviTex units increased by 20% in the fourth quarter and 22% for the entire year. Similarly, PRS units grew by 12% in both the quarter and the full year, indicating robust demand and successful market penetration efforts.

LiquiFix revenue experienced remarkable expansion, more than tripling compared to the prior year. This surge points to rapidly growing adoption among surgeons and healthcare providers, positioning it as a key contributor to future revenue streams.

European sales played a significant role, comprising 15% of total revenue at $12.1 million for the year, which represented a 17% year-over-year increase. This growth reflects the strength of the company’s international operations and strategic investments in key markets.

Gross margins improved to 66% for the fourth quarter and 68% for the full year, up from previous periods. The enhancement was primarily due to reduced excess and obsolete inventory write-offs, demonstrating better inventory management and operational efficiency.

Sales and marketing expenses amounted to $14.5 million in the quarter and $63.2 million for the year. While there were year-over-year reductions in compensation, severance, consulting, and travel costs, these were partially offset by higher commissions tied to stronger revenue performance.

General and administrative expenses rose to $3.8 million for the quarter and $15.7 million for the year, showing a modest increase from prior periods as the company continued to invest in administrative infrastructure.

Research and development expenses were $2.1 million in the quarter and $9.2 million for the full year, up slightly from the previous year, reflecting ongoing commitment to innovation and pipeline advancement.

The loss from operations narrowed to $6.6 million in the fourth quarter and $33.8 million for the full year, improvements from the prior year’s figures of $8.4 million and $34.1 million, respectively. Net loss stood at $9.0 million for the quarter and $38.8 million for the year, compared to $9.2 million and $37.8 million last year.

The company ended the period with a strong cash position of $50.8 million, bolstered by debt refinancing and an incremental equity raise, providing enhanced financial flexibility for future initiatives.

Forward-Looking Guidance

For 2026, management anticipates at least 8% revenue growth over the prior year. First-quarter revenue is projected to be approximately $18.5 million. These projections take into account the ongoing ramp-up of newly hired sales representatives and the complexities associated with contract implementations.

Commercial Developments

The company has significantly expanded its commercial team, with 40% of U.S. field representatives hired within the past six months. As of the call date, there were 88 U.S. quota-carrying territory managers, surpassing the previous target of 76. This expansion supports a refined strategy focused on deeper account penetration and operational efficiency.

A comprehensive commercial restructuring has been implemented, including new U.S. commercial leadership, a redefined sales talent profile, and an optimized compensation plan. These changes aim to enhance focus on high-volume accounts and improve overall sales execution.

Product innovation remains a priority, with the launch of OviTex LTR and the enrollment of the first patients in the ECHO hiatal hernia clinical trial. Additionally, Dr. Howard Lang was appointed as Chief Medical Officer effective March 1, bringing extensive expertise to drive clinical engagement and surgeon education.

Strategic Risks and Considerations

Management highlighted several factors influencing the conservative guidance, including the ramp-up period for newly hired sales reps and the variability in contract implementation across hospitals. CEO Antony Koblish emphasized the need for prudent planning to ensure strong execution amid these transitions.

CFO Roberto E. Cuca noted that while operating and net losses are expected to continue declining throughout the year, there may be a step-up in losses from Q4 to Q1 due to seasonal revenue patterns, territory restructuring, a shift away from smaller peripheral hospitals, and weather-related disruptions in January affecting elective procedures.

Executive Summary

Leadership highlighted the successful completion of a major commercial rebuild, resulting in the largest and most targeted U.S. field team in the company’s history. The strategy has shifted toward concentrating efforts on dense, high-volume accounts rather than broad geographic coverage, fostering sustainable growth.

The product mix evolved positively, with notable unit growth in OviTex and PRS, though tempered by a shift toward lower-priced SKUs in hernia procedures, particularly in robotic and laparoscopic segments. European operations achieved double-digit growth on a stable infrastructure, while LiquiFix adoption accelerated, opening new revenue opportunities.

Financially, Q4 and full-year losses narrowed, supported by balance sheet improvements through debt refinancing and cash management. Guidance for Q1 and the full year was set conservatively, acknowledging organizational changes and short-term visibility challenges.

The year is positioned as an “execution year,” with emphasis on converting signed contracts into realized revenue. The new compensation structure incentivizes deeper penetration at target accounts, tracking metrics like user numbers per site, portfolio breadth, and local density.

Gross margin gains stemmed from lower inventory write-offs, and investments in sales training have accelerated new rep productivity ramps. Innovations like OviTex LTR and the ECHO trial, combined with the new CMO, promise further growth and surgeon engagement.

Industry Terminology

• OviTex: A specialized reinforced tissue matrix made from ovine rumen combined with polypropylene, primarily utilized in hernia repair procedures and abdominal wall reconstructions.
• OviTex PRS: A dedicated product line within the portfolio tailored for applications in plastic and reconstructive surgery, separate from the primary hernia repair offerings.
• LiquiFix: An innovative surgical fixation solution employed in hernia repairs, serving as a complementary product to the OviTex lineup.
• LTR: Refers to the long-term resorbable variant of OviTex, engineered to provide reinforcement during the healing process without relying on permanent synthetic polymer elements.
• IHR: Stands for Inguinal Hernia Repair, encompassing minimally invasive techniques addressed by TELA Bio’s specialized OviTex products.
• LPR: Encompasses Laparoscopic and Robotic Procedures, which are minimally invasive methods for hernia repair supported by the company’s product offerings.
• ECHO (trial): A dedicated clinical investigation assessing the performance of OviTex in robotic hiatal hernia repair surgeries.
• PRS: Plastic and Reconstructive Surgery, a key segment featured in TELA Bio’s financial reporting and product strategy.
• AMS: Advanced Medical Solutions, the strategic partner facilitating LiquiFix distribution and promoting its clinical uptake.

Full Earnings Call Transcript

Antony Koblish: Thank you, Louisa, and good afternoon, everyone. We appreciate you joining us for TELA Bio, Inc.'s fourth quarter and full-year 2025 earnings call. Today, I’ll begin by summarizing our key achievements throughout 2025 and sharing our perspective on the strategic path ahead. Following that, Jeffrey will delve into the core transformations we’ve implemented within our commercial operations and discuss their anticipated effects on upcoming performance. Roberto will then cover the financial details, after which we’ll open the floor for your questions. The year 2025, particularly the third and fourth quarters, marked a phase of substantial strategic evolution throughout the organization.

Since Jeffrey Blizard’s appointment as President in June, we’ve executed a thorough reconstruction of TELA Bio’s commercial framework. At the same time, we’ve upheld our dedication to enhancing operational efficiency and steadily progressing our product pipeline initiatives. These efforts enabled us to secure 16% revenue growth for the full year and reach record-high revenues in the fourth quarter. Delivering this growth while navigating such profound organizational shifts speaks volumes about the exceptional quality of our team and the compelling value offered by the OviTex product family. As we step into 2026, we boast the largest and most capable field sales team in our history, backed by a commercial approach crafted to deliver steady, reliable expansion.

Demand for our offerings continues to be robust, and the market potential in hernia repair alongside plastic reconstructive surgery remains vast. The foundational adjustments we pursued in 2025 were specifically designed to equip us with the commercial capabilities needed to reliably harness this demand. Our 2025 revenue expansion was propelled by outstanding results from our European operations, increased uptake of our IHR, LPR, and LiquiFix lines, and the steadfast contributions from our experienced U.S. sales representatives. Investing strategically in top-tier talent aligned with our ideal profile has been a cornerstone of this commercial overhaul.

A substantial segment of our roughly 90-person sales organization is still in the initial stages of their roles, with about 40% having onboarded in the last six months. This isn’t due to high turnover but represents a deliberate expansion of our commercial footprint and the recruitment of individuals perfectly suited to our evolving sales framework. We’re already observing that these recent additions are surpassing the early performance of their predecessors during onboarding, which bodes well for their ability to execute our strategy with greater effectiveness.

In the fourth quarter, we intensified our initiatives to fortify the U.S. commercial organization by accelerating hiring to achieve our sales personnel goals and establishing the necessary support systems for these newcomers. This encompassed commitments to comprehensive training programs, the introduction of advanced sales enablement resources, the rollout of a revamped U.S. sales leadership framework, and the overhaul of the 2026 compensation structure to better synchronize with our growth objectives and performance benchmarks. Looking toward 2026, our efforts center on two primary strategic priorities for expansion. Paramount among them is our resolve to preserve the positive trajectory from 2025 and pursue additional sales increases in both the U.S. and Europe via superior talent acquisition, refined processes, and empowered commercial leadership.

Jeffrey and his team have achieved remarkable strides to date, and we anticipate continued enhancement as the refreshed commercial structure matures and our veteran reps reach peak performance. I’ll allow Jeffrey to elaborate on the details, but I’m highly optimistic about the solid commercial groundwork we’ve established. Secondly, we’re intensely dedicated to delivering the premier soft tissue reconstruction portfolio available. Innovation in products is central to TELA Bio’s essence, and we expect to unveil further product introductions throughout the year to capture greater market share in the vast U.S. landscape.

The demand for our cutting-edge solutions is evident; we’ve constructed a commercial backbone, fortified by an ever-growing product range, capable of steadily converting that demand into results. In support of this, we’re thrilled to announce Dr. Howard Lang’s elevation to Chief Medical Officer, effective March 1. Howard has been with TELA Bio for nearly two years and has played a pivotal role in our interactions with the surgical community. With more than three decades in plastic and reconstructive surgery, he possesses intimate knowledge of the market dynamics, including the procedures involved, persistent unmet needs, and surgeon preferences.

In his role as CMO, he will spearhead efforts to raise surgeon awareness, facilitate clinical training, and champion the creation, sharing, and application of the expanding clinical evidence supporting OviTex to foster wider market recognition and adoption. On the European front, our teams remain steady, experienced, and exceeding expectations. The competitive environment in Europe varies from the U.S., influenced by pricing strategies and bundling practices, yet we’re pleased with the swift embrace of OviTex in regions like the U.K. and the Netherlands. Our market share gains stem from patient outcomes and product performance, rather than price concessions or hospital-mandated volume commitments.

Looking ahead, we have a targeted expansion strategy for continental Europe, viewing it as a vital engine for growth in the years to come. In general, the Q4 outcomes mirrored a commercial organization in flux, yet we take great pride in the team’s accomplishments and their ongoing potential. Over the latter half of 2025, we accomplished a sweeping commercial enhancement alongside several other critical company milestones. Within those six months, we introduced OviTex LTR, a valuable new portfolio member that delivers lasting support through the healing phase and offers surgeons a biologically derived option over traditional synthetic meshes.

We initiated patient enrollment in our ECHO hiatal hernia study, which will bolster our clinical data and expand our reach to surgeons specializing in predominantly robotic procedures. We fortified and expanded our debt financing to solidify our balance sheet for upcoming challenges. Moreover, we enhanced our Board of Directors with fresh specialized knowledge. To encapsulate, 2025 was defined by intentional foundational transformations demanding resolve and focus; those efforts are now complete, and we’re directing our attention to 2026’s opportunities. I’ll now pass the discussion to Jeffrey for an in-depth exploration of our commercial strategy and reorganization.

Jeffrey Blizard: Thanks, Antony. As Antony outlined, it’s crucial not to overlook that, even amidst sweeping transformational reorganization, we achieved 16% revenue growth and marked our third consecutive quarter of sequential increases. We surpassed $80 million in total sales for fiscal 2025, all while upholding fiscal prudence and enhancing operational leverage. The sweeping modifications initiated since my arrival in June could have severely disrupted productivity and expansion in many organizations. That wasn’t the case here. This outcome highlights the unwavering dedication of the entire TELA Bio team and their commitment to serving patients and clients effectively.

I’d like to offer a thorough examination of the precise alterations to our commercial structure that Antony mentioned. I’ll also spotlight the advancements realized so far and how they position us for substantial progress ahead. First, we overhauled and restructured the U.S. commercial leadership. By adopting a new sales general manager model, we positioned decision-making nearer to clients, enabling teams to address needs promptly. Simultaneously, we dismantled organizational silos that had hindered inter-team synergy. We bolstered our sales leadership roster by elevating five critical senior positions.

These adjustments were crafted to heighten field accountability, streamline coordination between hernia and PRS divisions, and ensure uniform execution throughout our commercial operations. Next, we established structured promotion tracks within the commercial ranks, fostering upward career progression that recognizes high achievers and motivates substantial organizational contributions. We also recalibrated the U.S. sales talent criteria and expedited recruitment. We attained our 76 territory manager goal in Q3, and currently stand at 88 quota-carrying territory managers in the U.S., with one more hire pending and five positions in active recruitment.

Consequently, no additional net hiring is planned for the rest of 2026. The personnel required to meet our annual objectives are predominantly assembled. As Antony noted, we segment our field teams by cohorts, evaluating performance based on tenure and ramp trajectories. About 40% of the U.S. field staff onboarded in the past two quarters. They’re in nascent ramp phases, and we project their contributions will escalate quarterly as they forge account ties and build clinical expertise.

Another group, with 6 to 18 months tenure, has established solid momentum, with most hitting key productivity thresholds. They’re cultivating account networks while honing clinical skills, and we foresee their output rising notably each quarter. Lastly, our core of veteran reps, averaging over $1 million annually and reliably surpassing targets across all periods, comprises around 35% of the current roster.

As part of redefining sales talent, we’ve transformed our recruitment methodology. We’ve excelled in retaining elite performers and drawing in superior candidates. We’ve amplified investments in sales training to shorten the path from hire to peak effectiveness. New recruits exhibit superior performance and elevated evaluation scores compared to past groups. Our ideal profile merges sharp intellect, resilience, relationship-building prowess, and progressive clinical mastery. This departs from prior emphases on extensive soft tissue sales backgrounds.

The quality of incoming reps exceeds any prior standard, establishing TELA Bio as a prime destination for those matching our success blueprint. With reduced weight on prior experience, there’s an onboarding curve via our clinical programs. However, bolstered training enables swift clinical proficiency, after which their energy yields outsized results versus predecessors. While full ramp-up remains 6-9 months, their mature impact will surpass prior benchmarks.

We’ve launched a sophisticated sales enablement initiative leveraging enhanced market intelligence to guide leaders and reps in prioritizing efforts optimally. We’ve also instituted a 2026 compensation scheme promoting intensive target account penetration. This shifts from broad, superficial coverage to concentrated density at high-volume sites, nurturing multiple users per location for enduring revenue.

The comp overhaul explicitly supports this direction, extending to reduced geographic spans for reps, boosting efficiency and expense control. We’re amplifying executive field involvement; Antony recently engaged key accounts, as have I and others. This underscores our priority: forging profound physician bonds. We’ve refocused sales and marketing on OviTex’s unique mechanism and differentiating science. Surgeons value our data on sustained outcomes. OviTex’s ovine rumen integration sets it apart from legacy biologics, synthetics, or hybrids, anchoring surgeon adoption rationale.

We’ve heightened emphasis on LiquiFix, backed by AMS partners. Beyond superior fixation, it introduces OviTex to new hernia surgeons. Finally, we’ve embedded spending rigor, freeing resources for expanded customer education and training. This aligns with adoption stages while lifting margins. Collectively, with cohort performance on track, we’re assured of at least 8% 2026 revenue growth over 2025. For largely complete Q1, we guide to about $18.5 million.

The six-month change scope was vast, and sustaining momentum demands focus. Our Q1-end goal ensures 2026 captures full benefits. We’re progressing steadily, with all major changes enacted. Guidance incorporates variability from this rapid evolution. Notably, H2 annualization of restructuring, new cohort ramps, and pipeline/clinical pushes set sustainable outcomes. I’ll hand to Roberto for Q4 and full-year financials.

Roberto E. Cuca: Thank you, Jeffrey. Q4 2025 revenue rose 18% year over year to $20.9 million, with full-year growth at 16% to $80.3 million. OviTex grew 12% and OviTex PRS 20% annually. Expansion stemmed from new customers, international gains, and larger PRS U.S. units, partly offset by hernia mix favoring smaller IHR sizes. OviTex units rose 20% quarterly and 22% yearly; PRS units 12% both periods.

LiquiFix revenue tripled versus 2024, signaling initial traction expanding with OviTex. Europe contributed 15% or $12.1 million, up 17% from $10.3 million, driven by key market progress and global access investments. Gross margin hit 66% Q4 and 68% yearly, versus 64%/67% prior, aided by lower excess/obsolete inventory costs relative to revenue.

Sales/marketing costs were $14.5 million Q4 and $63.2 million yearly, versus $14.0 million/$64.6 million prior. Revenue-tied commissions increased, offset by reduced compensation, severance, consulting, travel annually. G&A was $3.8 million Q4/$15.7 million yearly, up from $3.6 million/$14.7 million. R&D: $2.1 million Q4/$9.2 million yearly, versus $2.0 million/$8.8 million.

Operating loss: $6.6 million Q4/$33.8 million yearly, improved from $8.4 million/$34.1 million prior. Net loss: $9.0 million Q4/$38.8 million yearly, versus $9.2 million/$37.8 million. Cash closed at $50.8 million, enhanced by debt refinance and equity raise. For 2026, revenue growth at least 8%; Q1 ~$18.5 million. Operating/net losses to decline yearly/quarterly, with Q1 step-up from Q4 amid revenue dynamics.